» Articles » PMID: 35956339

Association Between Coronary Artery Plaque Progression and Liver Fibrosis Biomarkers in Population with Low Calcium Scores

Overview
Journal Nutrients
Date 2022 Aug 12
PMID 35956339
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The severity of nonalcoholic fatty liver disease (NAFLD) has been found to be associated with atherosclerosis burden. However, whether liver fibrosis scores can be used to predict atherosclerosis progression, especially for patients with low calcium scores, remains undetermined. Methods: A total of 165 subjects who underwent repeated coronary computed tomography angiography (CCTA) and had low calcium scores (<100) were enrolled. The segment stenosis score (SSS) from the CCTA was measured, and the association between SSS progression and biochemical parameters was analyzed in addition to liver fibrosis scores, including nonalcoholic fatty liver disease fibrosis score (NFS), fibrosis-4 index (FIB-4), aspartate aminotransferase (AST) to platelet ratio index (APRI), and Forns score. Results: When compared with those without plaque at baseline (SSS = 0), subjects with plaque had higher blood pressure, higher coronary artery calcium (CAC) scores, and higher liver fibrosis scores, including Forns score, Fib-4, and NFS. During the medium follow-up interval of 24.7 months, 60 (39.4%) patients displayed SSS progression, while the remaining 105 (63.6%) patients showed no CAD progression. In a multivariate analysis, being male having a high diastolic blood pressure (DBP), and having a high NFS liver fibrosis score were independently associated with the odds ratio for SSS progression. Conclusions: Higher baseline blood pressure and liver fibrosis markers are associated with the presence of coronary artery disease (CAD) plaques in subjects in early CAD stages. For disease progression, the male gender, DBP, and NFS appear to be independently associated with coronary atherosclerosis plaque progression in subjects with low calcium scores.

Citing Articles

Association of Liver Fibrosis Markers with Mortality Outcomes in Patients with Chronic Kidney Disease and Coronary Artery Disease: Insights from the NHANES 1999-2018 Data.

Ye Z, Xie E, Guo Z, Gao Y, Han Z, Dou K Cardiorenal Med. 2025; 15(1):153-163.

PMID: 39837280 PMC: 11844702. DOI: 10.1159/000543500.


Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.

Cheng P, Chen W, Hou C, Lin C, Chang M, Wang C Clin Mol Hepatol. 2023; 30(1):16-36.

PMID: 37793641 PMC: 10776290. DOI: 10.3350/cmh.2023.0315.


Fibrosis score 4 index has an independent relationship with coronary artery diseases in patients with metabolic-associated fatty liver disease.

Namakchian M, Rabizadeh S, Seifouri S, Asadigandomani H, Arab Bafrani M, Seifouri K Diabetol Metab Syndr. 2023; 15(1):57.

PMID: 36964605 PMC: 10039491. DOI: 10.1186/s13098-023-01031-y.

References
1.
Miptah H, Ramli A, Mohamad M, Hashim H, Tharek Z . Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: is there an association?. BMC Fam Pract. 2020; 21(1):238. PMC: 7679975. DOI: 10.1186/s12875-020-01306-7. View

2.
Villines T, Hulten E, Shaw L, Goyal M, Dunning A, Achenbach S . Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: results from the CONFIRM (Coronary CT Angiography.... J Am Coll Cardiol. 2011; 58(24):2533-40. DOI: 10.1016/j.jacc.2011.10.851. View

3.
Nissen S, Tuzcu E, Libby P, Thompson P, Ghali M, Garza D . Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 292(18):2217-25. DOI: 10.1001/jama.292.18.2217. View

4.
Kronmal R, McClelland R, Detrano R, Shea S, Lima J, Cushman M . Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2007; 115(21):2722-30. DOI: 10.1161/CIRCULATIONAHA.106.674143. View

5.
Onnerhag K, Hartman H, Nilsson P, Lindgren S . Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scand J Gastroenterol. 2019; 54(3):328-334. DOI: 10.1080/00365521.2019.1583366. View